Scandion Oncology A/S

OM:SCOL Stock Report

Market Cap: SEK 17.3m

Scandion Oncology Future Growth

Future criteria checks 2/6

Scandion Oncology is forecast to grow earnings and revenue by 69.7% and 39.5% per annum respectively. EPS is expected to grow by 106.9% per annum. Return on equity is forecast to be -60.3% in 3 years.

Key information

69.7%

Earnings growth rate

106.9%

EPS growth rate

Biotechs earnings growth44.5%
Revenue growth rate39.5%
Future return on equity-60.3%
Analyst coverage

Low

Last updated12 Nov 2024

Recent future growth updates

Recent updates

We Think Scandion Oncology (STO:SCOL) Needs To Drive Business Growth Carefully

Aug 02
We Think Scandion Oncology (STO:SCOL) Needs To Drive Business Growth Carefully

Companies Like Scandion Oncology (STO:SCOL) Are In A Position To Invest In Growth

Feb 01
Companies Like Scandion Oncology (STO:SCOL) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Scandion Oncology's (STO:SCOL) Cash Burn Situation

May 26
Here's Why We're Not Too Worried About Scandion Oncology's (STO:SCOL) Cash Burn Situation

We're Hopeful That Scandion Oncology (NGM:SCOL) Will Use Its Cash Wisely

Jan 06
We're Hopeful That Scandion Oncology (NGM:SCOL) Will Use Its Cash Wisely

Earnings and Revenue Growth Forecasts

OM:SCOL - Analysts future estimates and past financials data (DKK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-4-4-41
12/31/202513-10-10-101
12/31/2024N/A-27-23-231
9/30/2024N/A-32-36-36N/A
6/30/2024N/A-36-33-33N/A
3/31/2024N/A-37-43-43N/A
12/31/2023N/A-39-51-51N/A
9/30/2023N/A-44-54-54N/A
6/30/2023N/A-59-69-69N/A
3/31/2023N/A-73-69-69N/A
12/31/2022N/A-77-70-69N/A
9/30/2022N/A-76-68-67N/A
6/30/2022N/A-66-57-57N/A
3/31/2022N/A-56-57-56N/A
12/31/2021N/A-52-50-50N/A
9/30/2021N/A-43-48-48N/A
6/30/2021N/A-31-34-34N/A
3/31/2021N/A-22-24-24N/A
12/31/2020N/A-17-17-17N/A
9/30/2020N/A-11-8-8N/A
6/30/2020N/A-14-14-14N/A
3/31/2020N/A-14-12-12N/A
12/31/2019N/A-12-10-10N/A
9/30/2019N/A-17-21-21N/A
6/30/2019N/A-12-16-16N/A
3/31/2019N/A-10-15-15N/A
12/31/2018N/A-8-13-13N/A
9/30/2018N/A-4-3-3N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SCOL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SCOL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SCOL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SCOL's revenue (39.5% per year) is forecast to grow faster than the Swedish market (1.2% per year).

High Growth Revenue: SCOL's revenue (39.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: SCOL is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 15:37
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Scandion Oncology A/S is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Soo RomanoffEdison Investment Research
Christian BinderRedeye